We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Royal Bank Of Scotland Group Plc | LSE:RBS | London | Ordinary Share | GB00B7T77214 | ORD 100P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 120.90 | 121.35 | 121.40 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
18/3/2020 16:55 | Yea I think markets will at least fall to around the 50 percent decline region | tfergi | |
18/3/2020 16:52 | Dow will go to 16000. | joe king1 | |
18/3/2020 16:44 | NO leg up until the USA starts to see the other side of this. Currently they are only at the start and the USA/UK/EU are in mass panic | dope007 | |
18/3/2020 16:34 | Looks like the Dow at 20,000 and the FTSE at 5000 both bouncing around at about 33 percent down are deciding the next leg. Up or down. | tfergi | |
18/3/2020 16:28 | The £ as others have said could be a function of repatriating funds back to the USA | dope007 | |
18/3/2020 16:13 | China reports new progress in drug, therapies against Covid-19 Researchers working at the drug centre for Covid-19 cure at a company in Wuqing District, north China's Tianjin Municipality. China has completed the clinical research of Favipiravir, an antiviral drug that has shown good clinical efficacy against the Covid-19 (coronavirus) outbreak, according to an official on Tuesday (March 17). - Xinhua/ANN BEIJING: China has completed the clinical research of Favipiravir, an antiviral drug that has shown good clinical efficacy against the Covid-19 (coronavirus) outbreak, according to an official on Tuesday (March 17). Favipiravir, the influenza drug which was approved for clinical use in Japan in 2014, has shown no obvious adverse reactions in the clinical trial, said Zhang Xinmin, director of the China National Center for Biotechnology Development under the Ministry of Science and Technology, at a press conference. More than 80 patients have participated in the clinical trial in The Third People's Hospital of Shenzhen, south China's Guangdong Province, including 35 patients taking Favipiravir and 45 patients on a control group. Results showed that patients receiving Favipiravir treatment turned negative for the virus in a shorter time compared with patients in the control group. A multi-centred randomised clinical study led by the Zhongnan Hospital of Wuhan University also suggested that the therapeutic effect of Favipiravir is much better than that of the control group. Favipiravir has been recommended to medical treatment teams and should be included in the diagnosis and treatment plan for Covid-19 as soon as possible, Zhang said. | stonedyou | |
18/3/2020 14:44 | Over reaction it may be but the over reaction has caused a complete collapse in demand, job losses, SME bankruptcies etc, etc. Buying here is mental as earnings are going to collapse and recovery will take time. Destroyed pensions, lost jobs, etc, etc do not start spending in 2 months time | dope007 | |
18/3/2020 14:35 | and in 4 - 6 weeks the press will have moved on to a new story. I still think this is massive overreaction. Panic is the worst danger or them all! | cfc1 | |
18/3/2020 13:03 | We will be to a point and of course trade negotiations are needed. Perhaps this virus will make those negotiations a lot smoother as both sides realise they need to trade and trade smoothly!!! | dope007 | |
18/3/2020 12:53 | I suspect we are still on the hook. | maxk | |
18/3/2020 12:51 | Which makes no sense. The EU are financially screwed. You have Germany trying to support the rest. The UK now supports nobody | dope007 | |
18/3/2020 12:46 | I have just read that the pound against the euro is lower than the worst Brexit level and worst since about 1985 | tfergi | |
18/3/2020 11:45 | Someone thinks so. Cant see it myself. | maxk | |
18/3/2020 11:41 | Meanwhile the £ continues to fall against the €. No explanation is offered as to why over the last month it has fallen from €1.20 to €1.08. Is the UK seen as 10% weaker than the Eurozone (which includes Italy) than a month ago? | leedskier | |
18/3/2020 11:32 | tfergi, I agree. I was merely giving maxk the market spin for its daily trading ... which is much enhanced by the volatility. | leedskier | |
18/3/2020 11:26 | To be fair he said if it needed more then He would make it available | tfergi | |
18/3/2020 11:15 | I read that the market does not think £330bn is enough to offset the incoming hit to GDP. | leedskier | |
18/3/2020 10:59 | FTSE 5000 is a big physiological barrier it seems | tfergi | |
18/3/2020 10:44 | It would be sensible to cancel the div to hold more cash in the bank rbs should stop the div , and do it now Rbs should cancel the div till the markets are back to normal | portside1 | |
18/3/2020 09:09 | prtside are you dephiboy in disguise ?? Read what Leeds wrote before - your comments on here will not cause a 'corona panic' On Corona - best quote so far WW - Elon Musk " danger of panic still far exceeeds danger" | cfc1 | |
18/3/2020 08:26 | European regulators moved to rein in short-selling, ordering hedge funds and other traders to disclose more information when they bet that stocks will decline and signaling that more restrictions could come soon. Traders must inform regulators when their net-short positions account for at least 0.1% of a company’s share capital, down from 0.2%, according to the Paris-based European Securities and Markets Authority. The change, which goes into effect after markets close Monday, is being made to give regulators to more information to help with oversight. “ESMA considers that the current circumstances constitute a serious threat to market confidence” in... | leedskier |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions